Washington University School of Medicine
Welcome,         Profile    Billing    Logout  
 149 Trials 
231 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roth, Bruce J
NCT02643667: Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed
2
27
US
Ibrutinib, Radical prostatectomy
Washington University School of Medicine, Pharmacyclics LLC.
Prostate Cancer
04/23
04/23
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
CABIOS, NCT04477512: Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer ( Trial)

Active, not recruiting
1
18
US
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Washington University School of Medicine, Bristol-Myers Squibb, Exelixis
Metastatic Hormone Refractory Prostate Cancer
09/21
09/25
SWOG-S1823, NCT04435756: A Study of miRNA 371 in Patients With Germ Cell Tumors

Active, not recruiting
N/A
956
Canada, US, RoW
Biomarker Analysis, Blood Product Collection, Collection, Blood Products
SWOG Cancer Research Network, National Cancer Institute (NCI)
Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
06/26
10/26
Picus, Joel
NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
Europe, US, RoW
paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
06/31
06/31
NCT02643667: Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed
2
27
US
Ibrutinib, Radical prostatectomy
Washington University School of Medicine, Pharmacyclics LLC.
Prostate Cancer
04/23
04/23
NCT03866382: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting
2
314
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
02/25
02/25
CHAARTED2, NCT03419234: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Active, not recruiting
2
223
US
Abiraterone Acetate, CB7630, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Laboratory Biomarker Analysis, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
09/25
04/26
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Active, not recruiting
1/2
180
Europe, US
LAVA-1207, LAVA-1207 plus Pembrolizumab
Lava Therapeutics, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
04/27
04/27
CABIOS, NCT04477512: Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer ( Trial)

Active, not recruiting
1
18
US
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Washington University School of Medicine, Bristol-Myers Squibb, Exelixis
Metastatic Hormone Refractory Prostate Cancer
09/21
09/25
MK-6482-030, NCT06234605: A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Recruiting
1
80
US
HC-7366, Belzutifan, WELIREG™, MK-6482
HiberCell, Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
11/26
11/27
NCT06529822: Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Not yet recruiting
1
16
US
Synthetic long peptide personalized cancer vaccine, PCV, Poly ICLC, Hiltonol, Signatera assay
Washington University School of Medicine, Natera, Inc.
Muscle-Invasive Bladder Carcinoma
09/28
08/33
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
09/25
09/25
NCT00301379: Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients

Terminated
N/A
59
US
Observation data collection study.
Washington University School of Medicine
Cholangiocarcinoma
06/23
06/23
Govindan, Ramaswamy
ACCIO, NCT04267848: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial

Recruiting
3
1210
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Observation, Inspection, Visual Inspection, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
12/25
12/25
ALCHEMIST, NCT02193282: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An Treatment Trial)

Active, not recruiting
3
450
US
Clinical Observation, observation, Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Laboratory Biomarker Analysis, Placebo Administration
National Cancer Institute (NCI)
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
10/26
10/26
ALCHEMIST, NCT02201992: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An Treatment Trial)

Recruiting
3
168
US, RoW
Clinical Observation, Crizotinib, MET tyrosine kinase inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
05/36
05/36
NCT02299141: Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

Active, not recruiting
2
20
US
Nintedanib, Ofev, BIBF 1120, Vargatef
Washington University School of Medicine, National Comprehensive Cancer Network
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
01/20
12/24
NCT03916419: Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Active, not recruiting
2
26
US
ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel, Taxol, Carboplatin AUC, Paraplatin, Durvalumab, Imfinzi
Washington University School of Medicine
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
09/25
09/25
NCT04791839: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Checkmark Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Dec 2022 - Dec 2022: Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Active, not recruiting
2
30
US
Zimberelimab, Domvanalimab, Etrumadenant
Washington University School of Medicine, Arcus Biosciences, Inc.
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
01/25
04/29
NCT04397003: Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Recruiting
2
20
US
Neoantigen DNA vaccine, Durvalumab, Imfinzi, TDS-IM v2.0 Device, Peripheral blood draws
Washington University School of Medicine, AstraZeneca, Gateway for Cancer Research
Extensive-stage Small Cell Lung Cancer
03/28
03/30
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
KontRASt-01, NCT04699188 / 2020-004129-22: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting
1/2
344
Europe, Canada, Japan, US, RoW
JDQ443, TNO155, tislelizumab
Novartis Pharmaceuticals
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
04/26
04/26
NCT05616624: ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Recruiting
1/2
114
US
ADI-PEG 20, PEGylated arginine deiminase, Gemcitabine, Gemzar, Docetaxel, Taxotere
Washington University School of Medicine, Polaris Group
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
12/27
12/32
NCT04743505: Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
1/2
25
US
APL-101, Osimertinib, Tagrisso
Washington University School of Medicine, Apollomics Inc.
Metastatic Non Small Cell Lung Cancer
06/27
05/30
CLAMP, NCT05049863: Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate ( Trial)

Terminated
1
17
US
Mycophenolate Mofetil, MMF, Cellcept, Allopurinol, Zyloprim, Aloprim, Irinotecan, Onivyde, Camptosar
Washington University School of Medicine
Small-cell Lung Cancer, Small Cell Lung Carcinoma
11/24
11/24
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Recruiting
N/A
10000
Europe, Canada, US
Adaptimmune
Solid and Hematological Malignancies
11/25
11/25
ALCHEMIST Screening, NCT02194738: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The Trial)

Recruiting
N/A
8300
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, observation, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Crizotinib, Alkixen, Crizocent, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cytology Specimen Collection Procedure, Cytologic Sampling, Echocardiography, EC, Erlotinib, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
09/26
09/26
Ellis, Matthew J
FALCON, NCT01602380 / 2011-006326-24: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Active, not recruiting
3
462
Europe, Canada, Japan, US, RoW
faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
AstraZeneca
Hormone Receptor Positive Breast Cancer
04/16
12/24
Ma, Cynthia X
ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting
3
4220
US
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Stemline Therapeutics, Inc.
Breast Cancer
08/29
10/32
ALTERNATE, NCT01953588: Fulvestrant And/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery

Active, not recruiting
3
1473
US
fulvestrant, Faslodex®, anastrozole, Arimidex®
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
08/25
08/25
NCT03007979: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Completed
2
55
US
Palbociclib, Ibrance, Letrozole, Femara, Fulvestrant, Faslodex, Optional research biopsy, Goserelin, Zoladex, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Washington University School of Medicine, Pfizer
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
03/20
03/23
NeoPalAna, NCT01723774: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, not recruiting
2
84
US
PD0332991, Anastrozole, Arimidex®, Goserelin, Zoladex®, Decapeptide I, Surgery (standard of care), Tumor biopsy
Washington University School of Medicine, Pfizer
Breast Neoplasms
04/21
08/26
SWIFT RT, NCT06559540: Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Recruiting
2
220
US
Hypofractionated radiation, RT, Ultra-hypofractionated breast/chest wall and regional nodal radiation, SWIFT RT
Washington University School of Medicine
Node-positive Breast Cancer
04/34
04/34
NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting
2
50
US
FACT-B, Goserelin, Goserelin acetate, Zoladex, Anastrozole, Arimidex®, Exemestane, Aromasin®, Fulvestrant, Faslodex®, Tamoxifen, Nolvadex®, Archived tissue collection
Washington University School of Medicine, Genomic Health®, Inc.
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
01/26
07/31
NCT05255666: Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Withdrawn
2
42
NA
Pembrolizumab, Keytruda, Liposomal Irinotecan, NaI-IRI
Washington University School of Medicine, Merck Sharp & Dohme LLC, Ipsen
Triple Negative Breast Cancer, Brain Metastases
01/27
01/30
NeoTAILOR, NCT05837455: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Recruiting
2
81
US
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Washington University School of Medicine, Swim Across America, The Foundation for Barnes-Jewish Hospital
Breast Cancer, Cancer of the Breast
11/27
11/27
NCT04331067: Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Active, not recruiting
1/2
15
US
Paclitaxel, Taxol, Carboplatin, Paraplatin, Nivolumab, Opdivo, BMS-936558, Cabiralizumab, BMS-986227, Tumor biopsy, Bone marrow, Blood draw
Washington University School of Medicine, Bristol-Myers Squibb
Triple Negative Breast Cancer
03/23
05/26
REVERT, NCT05384119: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Completed
1/2
6
US
TTI-101, Palbociclib, Ibrance ®, Aromatase inhibitor (AI), fulvestrant, ribociclib
Tvardi Therapeutics, Incorporated
Breast Cancer
04/24
04/24
NCT06374459: Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Recruiting
1/2
152
US
Zumsemetinib, ATI-450, Capecitabine, Zoledronic acid, Denosumab
Washington University School of Medicine, United States Department of Defense, Aclaris Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
05/32
05/32
NCT04606342: ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis

Not yet recruiting
1/2
150
US
ATI-450, Paclitaxel, Capecitabine, Antiresorptive Agents
Washington University School of Medicine, Aclaris Therapeutics, Inc., United States Department of Defense
Breast Cancer, Cancer of Breast
05/25
04/28
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
NCT03939897: Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Active, not recruiting
1
24
US
Abemaciclib, LY 2835219, LY-2835219, LY2835219, Verzenio, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Diagnostic Imaging, Medical Imaging, Echocardiography, EC, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ICI-182780, ICI182780, ZD 9238, ZD-9238, ZD9238, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
06/23
07/25
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
NCT00353483: Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting
N/A
300
US
Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
Washington University School of Medicine
Breast Neoplasms
08/25
08/25
NCT04968964: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Recruiting
N/A
55
US
DiviTum® TKa assay, Study Care Plans
Washington University School of Medicine, Biovica
Breast Cancer, Cancer of the Breast
08/27
09/29
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
NCT05977036: BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Recruiting
N/A
65
US
DiviTum® TKa assay, CDK4/6 + Endocrine therapy
Washington University School of Medicine, Biovica
Metastatic Breast Cancer, Unresectable Breast Cancer
09/34
09/34
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Tan, Benjamin
ICARuS, NCT01815359: Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

Active, not recruiting
2
292
US
Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin
Memorial Sloan Kettering Cancer Center, The Cleveland Clinic, Brigham and Women's Hospital, University of Miami, University of Pittsburgh Medical Center, Washington University School of Medicine
Appendix Cancer, Colorectal Cancer
09/26
09/26
NAPOLI-2, NCT04005339: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Recruiting
2
50
US
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Georgetown University, Ipsen
Advanced Biliary Tract Cancer
04/25
12/25
NCT04536077: Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated
2
16
US
CDX-301, CDX-1140, Research blood draw
Washington University School of Medicine, Celldex Therapeutics, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer
11/23
11/23
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT04412629: Cabozantinib in High Grade Neuroendocrine Neoplasms

Recruiting
2
32
US
Cabozantinib, Cabometyx, Blood for plasma biomarkers, Tissue biopsy
Washington University School of Medicine, Exelixis
High Grade Neuroendocrine Neoplasms
07/25
03/26
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Hourglass Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer
Recruiting
1/2
49
US
Epacadostat, INCB024360, Short-course radiation therapy, SCRT, CAPOX chemotherapy, FOLFOX chemotherapy
Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)
Rectal Cancer
07/27
08/30
NCT01061515: Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

Active, not recruiting
1
21
US
Intraperitoneal Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda
Washington University School of Medicine
Carcinoma
09/25
09/25
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
NCT06648434: MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting
1
51
US
Zunsemetinib, ATI-450, mFOLFIRINOX
Washington University School of Medicine, National Cancer Institute (NCI), Aclaris Therapeutics, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas
04/27
03/30
NCT05187182: CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Recruiting
1
42
US
CA-4948, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Trastuzumab, Herceptin, mFOLFOX7
Washington University School of Medicine, Curis, Inc., The Foundation for Barnes-Jewish Hospital
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
09/27
06/28
NCT00301379: Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients

Terminated
N/A
59
US
Observation data collection study.
Washington University School of Medicine
Cholangiocarcinoma
06/23
06/23
DO-IT Cohort, NCT06556446: Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants

Recruiting
N/A
2800
Europe, Canada, RoW
Tenecteplase and Alteplase
Insel Gruppe AG, University Hospital Bern, Swiss Stroke Trialist Association, Swiss Stroke Registry
Ischemic Stroke
03/26
12/26
NOM-ERA, NCT03904043: Non-Operative Management and Early Response Assessment in Rectal Cancer

Active, not recruiting
N/A
63
US
Radiation therapy, FOLFOX regimen, Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire, Rectal biopsy samples, Blood for ctDNA
Washington University School of Medicine
Adenocarcinoma of the Lower Rectum
08/24
04/26
NCT04354064: Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Recruiting
N/A
100
US
Washington University School of Medicine, Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, Skandalaris, The V Foundation for Cancer Research, National Institute of General Medical Sciences (NIGMS)
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
12/25
12/25
Naughton, Michael
NCT00353483: Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting
N/A
300
US
Peripheral blood draw, Breast tissue collection, Bone marrow biopsy
Washington University School of Medicine
Breast Neoplasms
08/25
08/25
Baggstrom, Maria Q
ACHIEVE Study, NCT06096844: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting
3
304
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
06/26
06/26
NCT03916419: Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Active, not recruiting
2
26
US
ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel, Taxol, Carboplatin AUC, Paraplatin, Durvalumab, Imfinzi
Washington University School of Medicine
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
09/25
09/25
NCT04791839: Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Checkmark Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Dec 2022 - Dec 2022: Fourth interim analysis data from ARC-7 trial in combination with domvanalimab and etrumadenant for previously treated NSCLC
Active, not recruiting
2
30
US
Zimberelimab, Domvanalimab, Etrumadenant
Washington University School of Medicine, Arcus Biosciences, Inc.
Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer
01/25
04/29
NCT04397003: Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Recruiting
2
20
US
Neoantigen DNA vaccine, Durvalumab, Imfinzi, TDS-IM v2.0 Device, Peripheral blood draws
Washington University School of Medicine, AstraZeneca, Gateway for Cancer Research
Extensive-stage Small Cell Lung Cancer
03/28
03/30
NCT04743505: Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
1/2
25
US
APL-101, Osimertinib, Tagrisso
Washington University School of Medicine, Apollomics Inc.
Metastatic Non Small Cell Lung Cancer
06/27
05/30
HEROEX-1, NCT06521554: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC

Recruiting
1
120
US
NVL-330
Nuvalent Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/26
03/26
CLAMP, NCT05049863: Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate ( Trial)

Terminated
1
17
US
Mycophenolate Mofetil, MMF, Cellcept, Allopurinol, Zyloprim, Aloprim, Irinotecan, Onivyde, Camptosar
Washington University School of Medicine
Small-cell Lung Cancer, Small Cell Lung Carcinoma
11/24
11/24
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
Adkins, Douglas
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NCT06589804: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Recruiting
3
158
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
11/29
11/29
NCT04966481: Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Recruiting
3
81
US
Palbociclib, Ibrance, Cetuximab, Erbitux
Washington University School of Medicine, Pfizer, The Joseph Sanchez Foundation
HPV-unrelated Head and Neck Squamous Cell Carcinoma
02/27
02/27
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
US
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
NRG-HN001, NCT02135042: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Active, not recruiting
2/3
685
Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
02/26
02/31
NCT02573493: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

Completed
2
96
US
nab-Paclitaxel, Abraxane, Cisplatin, cis-DDP, cis-Platinum II, cis-Diamminedichloroplatinum, DDP, Cetuximab, Erbitux®, Intensity-Modulated Radiation Therapy, IMRT
Washington University School of Medicine, Celgene Corporation
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck
12/19
07/24
NCT03621696: Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

Active, not recruiting
2
63
US
Cisplatin, Platinol®, Platinol-AQ®, Intensity modulated radiation therapy, IMRT, Intensity modulated proton therapy, IMPT, Surgery, FACT-H&N, MD Anderson Dysphagia Inventory, University of Michigan Xerostomia Index, Scale of Subjective Total Taste Acuity, Neck Dissection Impairment Index
Washington University School of Medicine
HPV Related Oropharyngeal Squamous Cell Carcinoma
03/21
03/26
Los Tres Paso, NCT03389477: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
26
US
Palbociclib, Ibrance, PD 0332991, Cetuximab, Erbitux, Cisplatin, Platinol-AQ, Platinol, Intensity-Modulated Radiation Therapy, IMRT, Tumor biopsy, Peripheral blood draw
Washington University School of Medicine, Pfizer
Head and Neck Squamous Cell Carcinoma
02/22
04/27
NCT02296684: Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
67
US
MK-3475 (neoadjuvant), SCH 900475, Pembrolizumab, Keytruda, Surgery, Intensity modulated radiation therapy, IMRT, Image-guided radiation therapy, IGRT, Cisplatin, cis-DDP, cis-Platinum II, cis-Diamminedichloroplatinum, DDP, MK-3475 (adjuvant), Peripheral blood
Washington University School of Medicine, Merck Sharp & Dohme LLC
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
04/22
12/25
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
CACTUX, NCT02270814: Cisplatin, Nab-Paclitaxel, and Cetuximab () in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
74
US
nab-paclitaxel, Abraxane, Albumin-bound paclitaxel, Paclitaxel protein-bound, Cisplatin, Cisplatinum, CDDP, cis-DDP, cis-Diamminedichloroplatinum, cis-Platinum II, DDP, Carboplatin, Paraplatin®, CBDCA, Cetuximab, Erbitux®
Washington University School of Medicine, Celgene Corporation
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
12/25
12/25
KEYNOTE-C34, NCT04811027 / 2021-000055-39: Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Checkmark Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Oct 2021 - Oct 2021: Initiation of TACTI-003 trial in combination with Keytruda for 1L HNSCC
Active, not recruiting
2
171
Europe, US, RoW
eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475
Immutep S.A.S., Merck Sharp & Dohme LLC
HNSCC
03/24
03/25
NCT05283226: Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Recruiting
2
46
US, RoW
NRC-2694-A, Paclitaxel
NATCO Pharma Ltd.
Carcinoma, Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma
12/24
01/25
KEYCHAIN, NCT03383094: Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Recruiting
2
114
US
Pembrolizumab, Immunotherapy, Radiation therapy, Radiotherapy, Cisplatin, Chemotherapy
Loren Mell, MD, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
12/25
12/26
NCT05074940: Amivantamab in Adenoid Cystic Carcinoma

Recruiting
2
18
US
Amivantamab
Trisha Wise-Draper
Salivary Gland Cancer
08/24
08/28
BA3021-002, NCT05271604: A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
290
US
Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab, Erbitux
BioAtla, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
12/26
12/26
NCT04831320: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Active, not recruiting
2
46
US
nab-paclitaxel, Abraxane, Nivolumab, Opdivo
Washington University School of Medicine, Bristol-Myers Squibb
Metastatic Head-and-neck Squamous-cell Carcinoma
12/25
09/26
MINT-2, NCT06702033: The Minimalist Trial-2

Not yet recruiting
2
153
US
Radiation therapy, Cisplatin, Surgery
Washington University School of Medicine, The Joseph Sanchez Foundation
HPV-Related Oropharynx Squamous Cell Carcinoma
01/30
04/33
NCT04852328: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Recruiting
2
30
US
CUE-101
Washington University School of Medicine, Cue Biopharma
Oropharyngeal Squamous Cell Carcinoma
10/27
10/27
NCT04643379: Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Active, not recruiting
2
30
US
Olaparib, Lynparza, Pembrolizumab, Keytruda, Carboplatin, Peripheral blood draw
Washington University School of Medicine, Merck Sharp & Dohme LLC, Joseph Sanchez Foundation
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
11/25
11/26
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
Rambro2, NCT05980000: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Recruiting
2
72
US
Ramucirumab, Cyramza, Pembrolizumab, MK-3475, Keytruda
Washington University School of Medicine, Eli Lilly and Company
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
04/28
04/31
 

Download Options